Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montréal, Saint-Hyacinthe, QC, Canada.
J Feline Med Surg. 2022 Oct;24(10):e330-e337. doi: 10.1177/1098612X221107795. Epub 2022 Jun 28.
The aim of this study was to evaluate the efficacy and tolerability of a 4% tetrasodium EDTA (tEDTA) infusion protocol in the subcutaneous ureteral bypass (SUB) devices of cats with intraluminal obstruction at a veterinary teaching hospital between July 2017 and April 2020.
This was a retrospective controlled study. Cats with an obstructed SUB device underwent a 4% tEDTA infusion protocol. Obstruction of the device was diagnosed based on renal pelvic dilation, dilatation of the ureter, mineralized material within the device (cystostomy or nephrostomy catheters) seen on ultrasound, the absence of visible bubbles within the renal pelvis and/or urinary bladder following ultrasound-guided flushing of the device with saline.
A total of 16 tEDTA infusion protocols were performed in 14 cats. The infusion protocol was considered successful in 11/16 SUB devices (68.8%). Six devices (n = 6/11; 54.5%) had recurrence of obstruction with a median time of 87 days. One or more episodes of self-limiting pollakiuria and/or hematuria following infusion was seen in eight patients (n = 8/14; 57.1%).
Infusions of 4% tEDTA successfully relieved intraluminal obstruction in patients with occluded SUB devices; however, the recurrence of obstruction was common. Additional studies evaluating case selection and optimal protocols are warranted.
本研究旨在评估 4%四钠乙二胺四乙酸（tEDTA）输注方案在 2017 年 7 月至 2020 年 4 月期间一家兽医教学医院中发生管腔内阻塞的猫的皮下输尿管旁路（SUB）装置中的疗效和耐受性。
这是一项回顾性对照研究。发生 SUB 装置阻塞的猫接受了 4% tEDTA 输注方案。根据肾盂扩张、输尿管扩张、超声可见装置内的矿物质物质（经皮肾造瘘或输尿管导管）、超声引导下用生理盐水冲洗装置后肾盂和/或膀胱内未见可见气泡来诊断装置阻塞。
共对 14 只猫的 16 个 tEDTA 输注方案进行了评估。16 个 SUB 装置中有 11 个（68.8%）被认为输注方案成功。6 个装置（n = 6/11；54.5%）在中位时间 87 天内再次发生阻塞。输注后有 8 只猫（n = 8/14；57.1%）出现一过性多尿和/或血尿。
4% tEDTA 输注成功缓解了 SUB 装置阻塞患者的管腔内阻塞；然而，阻塞的复发很常见。需要进一步的研究来评估病例选择和最佳方案。
